Medical Study Establishes First-Ever Long-Term Benefits for Macular Degeneration Sufferers Using Macular Health Vitamin Supplement
Posted on: Tuesday, 23 June 2009, 08:43 CDT
The second phase of the Multifocal Electroretinogram (MERG) study, conducted at the UAB Callahan Eye Foundation Hospital in
Complete MERG findings are available online at www.macularhealth.com
SOURCE Macular Health, LLC
Source: PR Newswire
Related Articles
- Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
- GARDASIL(R), Merck's Cervical Cancer Vaccine, Demonstrated Efficacy in Preventing HPV-Related Disease in Males in Phase III Study
- New Phase III Study in Previously Untreated HIV Patients Showed Merck's ISENTRESS(R) (Raltegravir) Reduced HIV Viral Load to Undetectable Levels, Comparable to Efavirenz, When Taken in Combination With Other Medicines
- Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients
- Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
- AstraZeneca Announces New Phase III Study of Vandetanib (ZACTIMA(R), ZD6474) in Patients With Advanced Lung Cancer
- Newly Released Phase III Studies for JANUVIA(TM), Merck's Investigational Once-Daily Medicine for Type 2 Diabetes, Showed Significantly Reduced Blood Sugar Levels When Used As Monotherapy or As Add-On Treatment
- Critical Therapeutics Announces Results From Phase II Study of Zileuton in Acne Patients
- Results of Short-Term Phase II Studies of Sitagliptin --MK-0431--, Merck's Investigational Treatment for Type 2 Diabetes, Presented at ADA
- AMEVIVE -- Alefacept -- Appears to Improve Patients' Psoriatic Arthritis in Phase II Study
User Comments (0)

RSS Feeds